Last10K.com

Halozyme Therapeutics, Inc. (HALO) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2020

Halozyme Therapeutics Inc

HISTORY TOOLS
CIK: 1737193 Ticker: HALO


Exhibit 99.1
halozymea20.jpg



HALOZYME REPORTS SIGNIFICANT RECENT ACHIEVEMENTS AND SECOND QUARTER 2020 RESULTS

- Reports First Quarter of Expected Sustainable Profitability and Maintains 2020 Guidance of $230 to $245 Million in Revenues and $0.60 to $0.75 Earnings Per Share -

- Two U.S. FDA Approvals and One EMA Approval Received by Partners for Products Utilizing Halozyme’s ENHANZE® Technology During Second Quarter -

- Recent FDA Approval of Roche’s PhesgoTM Allows for Home Administration by a Qualified Healthcare Professional -


SAN DIEGO, August 10, 2020 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2020 and provided an update on its recent corporate activities and outlook.

“The second quarter marked the achievement of multiple key milestones for Halozyme including two FDA approvals and one EMA approval for partnered drugs bringing the total number of FDA approved products utilizing our ENHANZE® drug delivery technology to five,” said Dr. Helen Torley, president and chief executive officer. “In addition, we are delighted to report that in the second quarter we delivered our first profitable quarter of expected sustainable profitability with earnings per share of $0.19. We see this as an important first step in our transformation to a high growth, high margin business delivering sustainable revenue growth and profitability over the long term. The events of the quarter were highlighted by our partner Janssen receiving approvals in both the U.S. and the EU for the subcutaneous form of DARZALEX® utilizing ENHANZE®, which is branded as DARZALEX FASPROTM in the U.S. We earned $25 million in total milestone payments from Janssen during the quarter, upon the first commercial sales in both markets. In late June, our partner Roche received FDA approval for Phesgo™, a fixed-dose combination of two monoclonal antibodies, Perjeta® and Herceptin®, utilizing our ENHANZE® technology for the treatment of patients with HER2-positive breast cancer. In addition to providing important new treatment options for patients, each of these newly-approved drugs represents the subcutaneous form of a growing, blockbuster franchise, and we expect their adoption to be an important driver of our growth and profitability in the coming years."

"I want to again express my gratitude to the Halozyme team, our partners and suppliers for their tireless work as we all navigate challenges posed by the COVID-19 pandemic," continued Dr. Torley. “Based on the latest information from our partners, I am pleased to report that we are maintaining our financial outlook for the full year 2020. It is possible that our partners’ timelines may change as a result of future changes related to COVID-19. We will continue to monitor this closely and provide updates as appropriate.”


The following information was filed by Halozyme Therapeutics Inc (HALO) on Monday, August 10, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Halozyme Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Halozyme Therapeutics Inc.

Continue

Assess how Halozyme Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Halozyme Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
Legal
Other
Filter Subcategory:
All
Product
Shares
Expense
Debt
Earnings
Geography
Other
Inside Halozyme Therapeutics Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Comprehensive Income (Loss) (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Stockholders' Equity (Unaudited)
Certain Balance Sheet Items
Certain Balance Sheet Items (Tables)
Certain Balance Sheet Items - Accounts Receivable, Net (Details)
Certain Balance Sheet Items - Accrued Expenses (Details)
Certain Balance Sheet Items - Deferred Revenue (Details)
Certain Balance Sheet Items - Inventories (Details)
Certain Balance Sheet Items - Prepaid Expenses And Other Assets (Details)
Certain Balance Sheet Items - Property And Equipment, Net (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Summary (Details)
Fair Value Measurement
Fair Value Measurement (Tables)
Fair Value Measurement - Assets Measured At Fair Value On A Recurring Basis (Details)
Fair Value Measurement - Components Of Available-For-Sale Marketable Securities (Details)
Fair Value Measurement - Contractual Maturities Of Available For Sale Debt Securities (Details)
Fair Value Measurement - Narrative (Details)
Long-Term Debt, Net
Long-Term Debt, Net - Narrative (Details)
Organization And Business
Revenue
Revenue (Tables)
Revenue - Accounts Receivable, Net And Deferred Revenues From Contracts (Details)
Revenue - Additional Revenue Information (Details)
Revenue - Amounts Under Collaborative Agreements (Details)
Revenue - Disaggregated Revenues (Details)
Revenue - Narrative (Details)
Share-Based Compensation
Share-Based Compensation (Tables)
Share-Based Compensation - Assumptions Used In The Black-Scholes Model (Details)
Share-Based Compensation - Narrative (Details)
Share-Based Compensation - Share-Based Compensation Expense (Details)
Share-Based Compensation - Unrecognized Estimated Compensation Cost (Details)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Narrative (Details)
Stockholders' Equity - Share Repurchase Activity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Income Taxes (Details)
Summary Of Significant Accounting Policies - Inventories (Details)
Summary Of Significant Accounting Policies - Leases (Details)
Summary Of Significant Accounting Policies - Net Income (Loss) Per Share (Details)
Summary Of Significant Accounting Policies - Restricted Cash (Details)
Summary Of Significant Accounting Policies - Revenue And Cost Of Product Sales (Details)
Summary Of Significant Accounting Policies - Segment Information (Details)

Material Contracts, Statements, Certifications & more

Halozyme Therapeutics Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: HALO
CIK: 1159036
Form Type: 10-Q Quarterly Report
Accession Number: 0001159036-20-000044
Submitted to the SEC: Mon Nov 02 2020 4:11:02 PM EST
Accepted by the SEC: Mon Nov 02 2020
Period: Wednesday, September 30, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/halo/0001159036-20-000044.htm